ICD-10 R53.83 is officially defined as "Other fatigue." code R53.83 is referenced in 9 tracked payer policy changes from Aetna and Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code R53.83 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Aetna considers blood lead testing medically necessary for diagnosis of persons with signs and symptoms of lead poisoning and for pregnant or lactating women who have any listed lead exposure risk factor. Lead screening is covered for persons with occupational lead exposure and, as a preventive service, for children in listed high-risk groups. Measurement of lead in bone, hair, teeth, or urine is considered experimental, investigational, or unproven.
Aetna considers blood lead testing medically necessary to diagnose people with signs or symptoms of lead poisoning, and for pregnant or lactating women who have any of the listed lead exposure risk factors. Routine blood lead testing for average-risk pregnant women without risk factors is not considered medically necessary. Lead screening is covered for persons with occupational lead exposure, which OSHA mandates, and as preventive care for children in high-risk groups under CDC, USPSTF, AAP and AAN guidance, while measuring lead in bone, hair, teeth or urine is considered experimental, investigational or unproven.
Aetna covers seat lift mechanisms as durable medical equipment only when the member cannot stand up from a regular armchair at home, has severe arthritis of the hip or knee or severe neuromuscular disease, the device is prescribed to effect improvement or arrest or slow deterioration, and the member can ambulate once standing. Stand-assist lifts, patient lifts, bariatric lifts, and multi-positional transfer systems are covered only when their own separate criteria are met, and spring-release seat lifts with a catapult-type motion are considered experimental, investigational, or unproven. the policy was last reviewed 07/16/2026.
Aetna considers a set of exclusionary tests medically necessary for evaluating members suspected of having chronic fatigue syndrome (CFS), with the selection depending on the case. These include ANA, blood and serum chemistries, CBC with differential, ESR, HIV serology, liver function tests, thyroid function tests, urinalysis, and MRI of the head to rule out multiple sclerosis. Aetna considers many other laboratory tests, procedures and treatments experimental, investigational or unproven for CFS, including cytokine assays, gene expression profiling, metabolomics, ondansetron, duloxetine, rituximab and Anakinra.
Serum free testosterone (CPT 84402) is medically necessary to distinguish a sex hormone-binding globulin (SHBG) abnormality from hypogonadism in obese males with symptoms of hypogonadism when total testosterone is low, to diagnose hyperandrogenism in symptomatic females, and in patients with a medical diagnosis that may increase or decrease SHBG levels. It is not medically necessary to diagnose testosterone deficiency in non-obese males with symptoms of hypogonadism, or when performed for screening of asymptomatic patients. Free testosterone should be performed by equilibrium dialysis, and free testosterone measured by an analog method should never be ordered.
Treatment of Lyme disease consists of oral antibiotics except for neuroborreliosis, Lyme carditis and Lyme arthritis. A 2- to 4-week course of IV antibiotics may be considered medically necessary for neuroborreliosis with objective neurologic complications of documented Lyme disease, and a single 2- to 4-week IV course may be considered for Lyme carditis or for the small subset of well-documented Lyme arthritis that is severe enough to need the rapid response of IV antibiotics. IV antibiotic therapy is considered investigational for conditions such as chronic fatigue syndrome or fibromyalgia without objective evidence of Lyme disease, post-Lyme syndrome, and repeat or prolonged courses longer than 4 weeks.
Injectable testosterone cypionate and testosterone enanthate do not require prior authorization, and prior authorization is only required for non-injectable testosterone formulations. For Androgel, Testim, or Testopel requests, testosterone replacement is medically necessary when the individual has a documented diagnosis of a pituitary tumor, Klinefelter's syndrome, Kallmann's syndrome, or bilateral orchiectomy, or a documented diagnosis of hypogonadism with signs and symptoms of low testosterone and two low total testosterone levels from morning samples collected between 8:00 a.m. and 10:00 a.m. on different days. Aveed, Axiron, Azmiro, Fortesta, Natesto, Vogelxo, Xyosted, and oral testosterone products are considered not medically necessary because other formulary options exist.
Testosterone replacement therapy may be considered medically necessary when the individual has a documented pituitary tumor, Klinefelter's syndrome, Kallmann's syndrome, or bilateral orchiectomy, or a documented diagnosis of hypogonadism with signs and symptoms of low testosterone and two low total testosterone levels from morning samples collected between 8:00 a.m. and 10:00 a.m. on different days. Injectable testosterone cypionate or injectable testosterone enanthate meets the therapy requirement directly, while Testopel requires documentation of an appropriate trial of both injectable products that did not adequately raise testosterone to within normal limits. Aveed and Azmiro are considered not medically necessary because other formulary options exist, and testosterone replacement is not medically necessary if the only symptom is erectile dysfunction or impotence.
Aetna clinical policy bulletin 0676 (reviewed October 7, 2026) covers prescription ReliefBand and PrimaBella devices for post-operative or chemotherapy-induced nausea that does not respond to antiemetics and conservative care, and for hyperemesis gravidarum that does not respond to conservative therapy. It treats other transcutaneous acupoint stimulation uses, such as motion sickness, autism, dysmenorrhea and fertility, as experimental, and does not cover over-the-counter disposable ReliefBand devices. The source gives a review date but no effective date.
Watch R53.83
Get one email when a payer policy names R53.83, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.